![]() |
Volumn 611, Issue , 2009, Pages 101-103
|
Discovery and optimization of a TRAIL R2 agonist for cancer therapy
a
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOKINE RECEPTOR AGONIST;
TRYPTOPHAN;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 2 AGONIST;
UNCLASSIFIED DRUG;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;
AMINO ACID SEQUENCE;
AMINO TERMINAL SEQUENCE;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BINDING AFFINITY;
CANCER CHEMOTHERAPY;
CARBOXY TERMINAL SEQUENCE;
DIMERIZATION;
DISULFIDE BOND;
DRUG BINDING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IMMUNOGENICITY;
OXIDATION;
PRIORITY JOURNAL;
PROTEIN STRUCTURE;
SIGNAL TRANSDUCTION;
DRUG DEVELOPMENT;
DRUG POTENTIATION;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
MASS SPECTROMETRY;
MOLECULAR GENETICS;
MOLECULAR MIMICRY;
NEOPLASM;
AMINO ACID SEQUENCE;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
DRUG DISCOVERY;
HUMANS;
MASS SPECTROMETRY;
MOLECULAR MIMICRY;
MOLECULAR SEQUENCE DATA;
NEOPLASMS;
RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;
|
EID: 66349130221
PISSN: 00652598
EISSN: None
Source Type: Book Series
DOI: 10.1007/978-0-387-73657-0_45 Document Type: Article |
Times cited : (13)
|
References (7)
|